Comparative Pharmacology
Head-to-head clinical analysis: OPANA versus ZIPAN 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPANA versus ZIPAN 25.
OPANA vs ZIPAN-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia by binding to opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking serotonin reuptake into presynaptic neurons.
5-20 mg orally every 4-6 hours as needed for pain; extended-release tablets: 5 mg orally every 12 hours, titrated up to 20 mg every 12 hours.
25 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 11-16 hours (mean 14 hours) in adults; prolonged in hepatic impairment (up to 30 hours) and elderly.
Terminal elimination half-life: 6-8 hours in adults; may be prolonged (up to 12 hours) in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily renal (approximately 90% as conjugated metabolites, 10% unchanged); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of unchanged drug (70-80%); fecal elimination accounts for 15-20% via biliary excretion; less than 5% as metabolites.
Category C
Category C
Opioid Analgesic
Opioid Analgesic